Elix, Inc. All rights reserved. Problem Setting KRAS mutations are associated with many cancers, but has poor ligandability. After several decades of work, covalent inhibitors against KRAS finally reached market. However, covalent inhibitors target only one mutant (G12C). Therefore, we need non-covalent inhibitors that target multiple mutants. Image Sources: Fell, J. B. et al., J. Med. Chem., Vol. 63, pp. 6679-6693 (2020), Kim, D. et al., Nature, Vol. 619, pp. 160–166 (2023) Our input data is only the crystal structure of Adagrasib with G12C KRAS, as well as common molecular descriptors and filters. Input Data 1. Determine optimal reward function structure for generative models. 2. Identify generated structures that may be good candidates. Study Objectives